Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-310 in Patients With Solid Tumors
NCT03076372Phase 1Unknown
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Jun 2018
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel liposomal (MM-310) in solid tumor, urothelial carcinoma (UC), Gastric carcinoma (GC) and 10 more, sponsored by Merrimack Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 18 months. Status: unknown.
02
Drugs
docetaxel liposomal (MM-310)
03
Conditions
solid tumorurothelial carcinoma (UC)Gastric carcinoma (GC)esophageal carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03076372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03076372.